PF-4942847, a novel oral Hsp90 inhibitor, has emerged as a candidate compound for clinical development in TNBC by synergistically targeting multiple signaling pathways. Furthermore, the degradation of AKT in PBLs may serve as a biomarker in clinical development.
Molekulargewicht:
516.3
CAS Nummer:
[1046859-34-0]
Formel:
C20H18Cl2F3N7O2
T202922
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten